Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Dose Escalation Study of IG3018 to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.
100 Clinical Results associated with Intelligem Therapeutics Australia Pty Ltd.
0 Patents (Medical) associated with Intelligem Therapeutics Australia Pty Ltd.
100 Deals associated with Intelligem Therapeutics Australia Pty Ltd.
100 Translational Medicine associated with Intelligem Therapeutics Australia Pty Ltd.